Is CareDx, Inc. (CDNA) Overvalued?
We dive into why CareDx, Inc. (CDNA) could be considered overvalued on 2026-08-04, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Commentary & Analysis
Which Is a Better Investment, CareDx, Inc. or uniQure N.V. Stock?
Learn more about whether CareDx, Inc. or uniQure N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why CareDx, Inc.’s (CDNA) Stock Is Up 12.77%
As of Monday, August 03, CareDx, Inc.’s CDNA share price has surged by 12.77%, which has investors questioning if this is right time to sell.Jenna Brashear
Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or CareDx, Inc. Stock?
Learn more about whether BioCryst Pharmaceuticals, Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, CareDx, Inc. or Ionis Pharmaceuticals, Inc. Stock?
Learn more about whether CareDx, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,318.2 | $269.0 | 56% |
|
| Shares Out (Mil) | 51.5 | 52.3 | 49% |
|
| Institutional Ownership | 95.5% | 92.2% | 68% |
|
| Float (Mil) | 49.3 | 39.8 | 47% |
|
| Beta | 2.42 | 0.93 | 96% |
|
| Avg Daily Volume (000s) | 1,378 | 488 | 75% |
|
| Price Change (52-week) |
248.7% | 56.4% | 98% |
|
| Growth | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.6% | 13.6% | 72% |
|
| Net Income (5yr) | (2.7%) | (10.1%) | 36% |
|
| EPS (5yr) | 0.1% | 16.0% | 31 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.6%) | (15.6%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | $0.250 | $1.213 | $1.355 | |
| Month Ago EPS | $0.188 | $0.934 | $1.134 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.188 | $0.934 | $1.134 | |
| Year/Year Chg | (87.9%) | (402.5%) | (583.8%) | |
| Financials | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $458 | $38 | 40% |
|
| Net Income (TTM) (Mil) | $111 | ($44) | 62% |
|
| EPS (TTM) | $2.153 | ($1.600) | 73% |
|
| Operating Cash Flow (TTM) (Mil) | $94 | ($31) | 52% |
|
| Net Cash Flow (TTM) (Mil) | $305 | $3 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $5 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,907 | $182 | 49% |
|
| Valuation | CDNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.42 | 2.76 | 79% |
|
| P/E | 21.1 | 19.1 | 52% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 211.4 | 0.9 | 100% |
|
| Ratios | CDNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 70.6% | 63.7% | 81% |
|
| Net Margin | 24.2% | (70.3%) | 83% |
|
| ROA | 22.7% | (50.0%) | 97% |
|
| ROE | 29.5% | (57.5%) | 87% |
|
| Liabilities to Assets | 20.1% | 30.3% | 13% |
|
| F-Score | 8 | 3 | 94% |
|
CareDx, Inc. did not pass any screens on 8/6/2026.
